Agonist anti-GITR antibody enhances vaccine-induced CD8 + T-cell responses and tumor immunity. Enhancing the immunostimulatory function of dendritic cells by transfection with mRNA encoding OX40 ligand. CD28-independent, TRAF2-dependent costimulation of resting T cells by 4-1BB ligand. CTLA-4: a moving target in immunotherapy. Tumor-mediated liver X receptor-α activation inhibits CC chemokine receptor-7 expression on dendritic cells and dampens antitumor responses. Induction of lymphoidlike stroma and immune escape by tumors that express the chemokine CCL21. Characterization of the CCL21-mediated melanoma-specific immune responses and in situ melanoma eradication. Antigen cross-presentation and T-cell cross-priming in cancer immunology and immunotherapy. Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells. Critical role for Sec22b-dependent antigen cross-presentation in antitumor immunity. WDFY4 is required for cross-presentation in response to viral and tumor antigens. Effective cancer immunotherapy by natural mouse conventional type-1 dendritic cells bearing dead tumor antigen. Cancer immunotherapy with immunomodulatory anti-CD137 and anti–PD-1 monoclonal antibodies requires BATF3-dependent dendritic cells. Expansion and activation of CD103 + dendritic cell progenitors at the tumor site enhances tumor responses to therapeutic PD-L1 and BRAF inhibition. Human CD141 + (BDCA-3) + dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens. Batf3 deficiency reveals a critical role for CD8 + dendritic cells in cytotoxic T cell immunity. Human inflammatory dendritic cells induce Th17 cell differentiation. Human blood CD1c + dendritic cells encompass CD5 high and CD5 low subsets that differ significantly in phenotype, gene expression, and functions. Transcription factor IRF4 drives dendritic cells to promote Th2 differentiation. IRF4 transcription factor-dependent CD11b+ dendritic cells in human and mouse control mucosal IL-17 cytokine responses. Similar antigen cross-presentation capacity and phagocytic functions in all freshly isolated human lymphoid organ-resident dendritic cells. A comparative study of the T cell stimulatory and polarizing capacity of human primary blood dendritic cell subsets. Differential uptake and cross-presentation of soluble and necrotic cell antigen by human DC subsets. Natural human plasmacytoid dendritic cells induce antigen-specific T-cell responses in melanoma patients. CpG-matured murine plasmacytoid dendritic cells are capable of in vivo priming of functional CD8 T cell responses to endogenous but not exogenous antigens. Single-cell RNA-seq reveals new types of human blood dendritic cells, monocytes, and progenitors. Unleashing type-2 dendritic cells to drive protective antitumor CD4+ T cell immunity. Critical role for CD103 +/CD141 + dendritic cells bearing CCR7 for tumor antigen trafficking and priming of T cell immunity in melanoma. Distinct progenitor lineages contribute to the heterogeneity of plasmacytoid dendritic cells. Development and function of dendritic cell subsets. Tumor microenvironment converts plasmacytoid dendritic cells into immunosuppressive/tolerogenic cells: insight into the molecular mechanisms. The role of type 1 conventional dendritic cells in cancer immunity. Dendritic cells and monocyte-derived cells: two complementary and integrated functional systems. The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting. Merad, M., Sathe, P., Helft, J., Miller, J. Decisions about dendritic cells: past, present, and future. A natural killer–dendritic cell axis defines checkpoint therapy–responsive tumor microenvironments.
NK cells stimulate recruitment of cDC1 into the tumor microenvironment promoting cancer immune control. Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity.
Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells. Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity. New insights into cancer immunoediting and its three component phases-elimination, equilibrium and escape. Hallmarks of cancer: the next generation.
0 kommentar(er)
